INTRODUCTION
============

Rapid and sensitive characterization of rare biomarkers in easily accessible bodily sources (e.g., fine needle aspirates, biopsies, and whole blood) will have significant impact on life sciences and clinical practice [@B1], [@B2]. Such diagnostic platforms could be used for screening and early diagnosis, comprehensive disease characterization in patients, and targeted therapy based on personal responses to treatments [@B3], [@B4]. Clinical detection technologies ideally should 1) provide high sensitivity and specificity, 2) enable rapid measurements with minimal sample processing, and 3) allow for multiple biomarker detection in a single parent sample (multiplexed detection) for accurate diagnosis [@B5]. A number of sensors fulfilling some of these criteria have been developed based on optical [@B6], [@B7], electronic [@B8], [@B9] or magnetic detection [@B10], [@B11]. The clinical adaptation of these systems, however, is still limited, because they often require lengthy sample purification or long assay times.

Biosensing strategies based on magnetic nanoparticles (MNPs) have recently received considerable attention. Magnetic fields experience little interference from native biological samples as most biological entities have negligible magnetic susceptibilities, similar to that of water (\~10^-6^). Even optically turbid samples thus will most often appear transparent to magnetic fields. However, when cells of interests are magnetically tagged, they will attain a high contrast against the biological background. To detect biomarkers using MNPs, various detection technologies have been developed [@B12]. These include techniques that use magnetometers, such as superconducting quantum interference device (SQUID) [@B13]-[@B15], magnetoresistive sensors [@B16]-[@B19], and Hall sensors [@B20], which directly measure the magnetic fields from magnetically-labeled biological targets.

We have recently developed a new magnetic sensing platform, diagnostic magnetic resonance (DMR) [@B21]. In contrast to direct detection of magnetic moments with magnetometers, which requires MNP-labeled targets to be closely positioned to the sensing elements, DMR exploits nuclear magnetic resonance (NMR) as the detection mechanism. When placed in NMR magnetic fields, MNPs create local magnetic fields, which change the relaxation rate of surrounding water molecules [@B22]. The mechanism simplifies and expedites the detection assays since the analytical signal is amplified and generated from the entire sample volume. By optimizing MNPs and miniaturizing NMR detectors, the DMR detection sensitivity for various target types have been considerably improved over the last few years. These developments nowadays enable rapid and multiplexed detection on a wide range of targets in microliter sample volumes, including nucleic acids [@B23], proteins [@B21], drugs, bacteria [@B24], and tumor cells [@B25]-[@B28]. With the recent integration of bioorthogonal targeting strategies [@B26], [@B29], [@B30] as well as accurate and real-time control of device temperature [@B31], the DMR platform has become more robust and sensitive, allowing operation in clinical settings [@B25]. This review will report on the latest developments of new MNPs and DMR systems for improving detection sensitivities. Specific biomedical and clinical DMR applications will also be discussed.

PRINCIPLE OF DMR ASSAY
======================

Due to their small size, MNPs assume unique physical properties which are different from those of bulk materials. The most salient feature is the paramagnetic behavior of an ensemble of small MNPs, termed *superparamagnetism* [@B32]. For most magnetic materials (e.g., ferrite and iron), MNPs with diameter of \< 20 nm have a single domain with magnetic moments confined in a particular direction defined by magnetic anisotropy. At sufficiently high temperature, thermal fluctuation can overcome the anisotropy barrier and spontaneously flip the magnetic moments of MNPs [@B33]. An ensemble of MNPs consequently displays negligible remnant magnetic moments in the absence of external magnetic fields, but the magnetic moments grow with increasing external magnetic fields. This superparamagnetic property ensures that MNPs do not spontaneously aggregate under physiological solutions. A MNP is typically comprised of an inorganic magnetic core and a biocompatible surface coating, which can be modified with functional ligands to confer the MNP with molecular specificity.

By producing local magnetic dipoles with strong spatial dependence, MNPs efficiently destroy the coherence in the spin-spin relaxation of water protons. The net effect is a change in magnetic resonance signal, which is measured as a shortening of the longitudinal (*T*~1~, spin-lattice) and transverse (*T*~2~, spin-spin) relaxation times. The capacities of MNPs to decrease *T*~2~ and *T*~1~ are respectively defined as the transverse (*r*~2~) and the longitudinal (*r*~1~) relaxivities. Typically, because the transverse relaxivities (*r*~2~) of MNPs are greater than their longitudinal relaxivities (*r*~1~), *T*~2~ is used for NMR-based biosensing applications. With a higher *r*~2~relaxivity, fewer numbers of nanoparticles are required to produce detectable *T*~2~ changes.

DMR detection exploits targeted MNPs to modulate the spin-spin *T~2~* relaxation time of biological samples. Depending on the size of the target biomarker, DMR assays can take two forms. For the detection of small molecular analytes such as metabolites, oligonucloetides, and proteins, magnetic relaxation switching (MRSw) effect can be exploited. MRSw relies on the changes of organizational state of MNPs in solution. When MNPs cluster in solution, the aggregates will assume different *r*~2~ values, causing corresponding *T*~2~ changes. MRSw assays are performed without removing excess unbound MNPs (**Fig. [1](#F1){ref-type="fig"}A**), and thereby facilitate the detection of small molecules. For larger biological targets such as bacteria, mammalian cells or cellular components, cell biomarkers can be tagged with functional MNPs and unbound MNPs are removed (**Fig. [1](#F1){ref-type="fig"}B**). This gain of magnetic moment (change of 1/*T~2~*) is proportional to the number of MNPs bound, and also indicative of the abundance of relevant biomarkers (**Fig. [1](#F1){ref-type="fig"}C**).

MAGNETIC NANOPARTICLES AND THEIR RELAXATION PROPERTIES
======================================================

Many different types of MNPs have been explored in an effort to maximize DMR detection sensitivity. In addition to having good stability in aqueous media, newer generations of MNPs are often engineered to have very high transverse relaxivity (*r~2~*) in order to induce pronounced *T~2~* changes. According to the outer-sphere model, the transverse relaxivity of a MNP is proportional to *τ~d~*·*M*^2^, where *τ~d~* is the residence time of water molecules around the particle and *M* is the particle magnetization [@B34]. The efforts to enhance *r*~2~ were thus focused on synthesizing larger MNPs using magnetically stronger materials.

Ferrite-based MNPs
------------------

Among different ferrite particles, cross-linked iron oxide (CLIO) nanoparticles have been widely used for DMR applications, notably because of their excellent stability and biocompatibility [@B35]. CLIO nanoparticles contain a superparamagnetic iron oxide core (3-5 nm monocrystalline iron oxide) composed of ferrimagnetic magnetite (Fe~3~O~4~) and/or maghemite (γFe~2~O~3~). The metallic core is coated with biocompatible dextran, before being cross-linked and functionalized with primary amine. Amine-terminated CLIO nanoparticles have an average hydrodynamic diameter of 25-40 nm, approximately 40-80 amines per nanoparticle for bioconjugation, and a *r~2~* of \~50 s^-1.^mM^-1^ \[Fe\] [@B23], [@B36].

To enhance the magnetization of ferrite nanoparticles, two main strategies have been employed, namely magnetic doping and nanoparticle sizing. Doping of ferrite with ferromagnetic elements such as manganese (Mn), cobalt (Co) or nickel (Ni) [@B24], [@B37], [@B38] has been shown to improve the MNP magnetization. Among the singly-doped ferrite MNPs, MnFe~2~O~4~ nanoparticles have the highest magnetization and *r~2~*value, on account of their electron spin configurations, followed by FeFe~2~O~4~, CoFe~2~O~4~, and NiFe~2~O~4~. More recently, it has been demonstrated that magnetization can be further enhanced via additional Zn^2+^doping in MnFe~2~O~4~ nanoparticles [@B39]. In addition, nanoparticle magnetization is known to increase with particle size [@B40]. Ideally, each magnetic spin within a bulk magnetic material would align parallel to the external magnetic field. However, in the nanoscale regime, surface spins tend to be tilted (spin canting), a feature that decreases the overall magnetic moment. By increasing the MNP size, this surface effect is reduced to increase the overall magnetization; the increase in particle size further enhances the particle *r~2~*.

Both magnetic doping and sizing strategies were employed by our laboratory to produce MnFe~2~O~4~nanoparticles with superior *r~2~* relaxivity [@B28]. These particles were synthesized by reacting iron (III) acetylacetonate \[Fe(acac)~3~\], manganese (II) acetylacetonate \[Mn(acac)~2~\] and 1,2-hexadecanediol at high temperature (300 °C). Through a seed-mediated growth approach, the magnetic core diameter was increased from 10 nm to 12, 16, or 22 nm. MnFe~2~O~4~nanoparticles with diameter ≤ 16 nm were found to be highly monodisperse and superparamagnetic at 300 K (**Fig. [2](#F2){ref-type="fig"}A**). The MNPs were subsequently rendered water-soluble using the small molecule meso-2,3-dimercaptosuccinic acid (DMSA) [@B24], [@B40], [@B41]. Due to DMSA\'s small size, the hydrodynamic diameter of MnFe~2~O~4~ nanoparticles was found to be smaller than that of CLIO nanoparticles, despite their larger magnetic core. More importantly, these MnFe~2~O~4~ nanoparticles assumed high relaxivities with *r~2~* values reaching 420 s^-1.^mM^-1^\[metal\] (equal to 6×10^−14^ *L*·s^−1^ per particle), more than 8 times greater than CLIO nanoparticles in metal basis (50 s^-1.^mM^-1^\[metal\] or 7×10^−16^ *L*·s^−1^ per particle) [@B28].

Fe-core MNPs
------------

Ferromagnetic metals, rather than their corresponding oxides, have been suggested as an ideal constituent for MNPs for their superior magnetization. This motivates the creation of Fe-core MNPs to achieve high *r~2~* relaxivities [@B42], [@B43]. However, because Fe cores are extremely reactive, monometallic MNPs typically require protective layers to prevent progressive oxidation.

Recently, a unique 16 nm Fe-core/ferrite shell MNP, known as "cannonball", has been developed for DMR applications (**Fig. [2](#F2){ref-type="fig"}B**) [@B44]. These structures are unique in that they contain elemental iron as core (not iron oxide) and a protecting oxide shell. These cannonballs were synthesized by thermally decomposing iron (0) pentacarbonyl \[Fe(CO)~5~\] to form the Fe core. A protective ferrite shell was formed by controlled oxidation with oxygen gas; this resulted in a thinner shell and retained a larger Fe core. The cannonballs were then coated with DMSA as described above. Because of their large Fe core, superparamagnetic cannonballs showed high magnetization (763 kA·m^-1^). The relaxivity of cannonballs is similar to that of MnFe~2~O~4~nanoparticles (6×10^−14^ *L*·s^−1^ per particle) (**Fig. [2](#F2){ref-type="fig"}D**).

We have further advanced Fe-core MNPs by developing a new synthetic approach for tunable core size and shell composition [@B45]. These new generation MNPs consist of an Fe core and an artificial ferrite shell (Fe\@MFe~2~O~4~, M = Fe, Mn, Co). The Fe cores were enlarged into a thermally stable ferromagnetic state to increase the overall magnetization. Instead of traditionally oxidizing the Fe core to form the shell, protective ferrite shells were grown onto the cores and metal-doped to further enhance magnetization. The resultant particles displayed a unique magnetic feature, the presence of hysteresis with negligible coercivity. Further analysis revealed a novel magnetization process wherein the shell effectively reduces the coercivity of the ferromagnetic cores by leading the magnetization process at small magnetic fields. The resulting particles, especially Fe\@MnFe~2~O~4~ MNPs (**Fig. [2](#F2){ref-type="fig"}C**) attained high saturation magnetization (796 kA·m^-1^) and *r~2~* (7×10^−14^ *L*·s^−1^ per particle; 430 s^-1^·mM^-1^\[metal\]) (**Fig. [2](#F2){ref-type="fig"}D**) but with negligible remanence to prevent inter-particle aggregations. When applied for DMR assays, these Fe\@MnFe~2~O~4~ MNPs achieved superior performance, capable of detecting picomolar avidin and single cancer cells in whole blood samples.

Bioorthogonal nanoparticle detection (BOND)
-------------------------------------------

In addition to the previous strategies to enhance MNP relaxivities, surface modification of particles and novel targeting approach also improve DMR sensing capacities. Bioorthogonal cycloaddition between a 1,2,4,5-tetrazine (Tz) and a trans-cyclooctene (TCO) is a fast and chemoselective reaction that does not require a catalyst, and can be used for small molecule labeling in serum [@B46], [@B47]. Recently, this chemistry has been successfully adapted to MNP targeting, and has been shown to improve nanoparticle binding valency and detection sensitivity. Termed \'bioorthogonal nanoparticle detection\' (BOND), this novel targeting platform employs Tz and TCO as the coupling agents [@B26]. Specific antibodies are first modified with TCO; once bound to cellular biomarkers of interest, the TCO-modified antibodies facilitate the coupling of Tz-modified nanoparticles (**Fig. [3](#F3){ref-type="fig"}**). Because of the small size of the coupling reagents, their high multiplicity on antibodies/nanoparticles resulted in higher nanoparticle binding to cells. This not only amplifies the biomarker signals but also significantly improves the detection sensitivity of DMR assays. Moreover, this platform is broadly-applicable for both extracellular and intracellular biomarker detection, and scalable for clinical uses [@B27], [@B48]. Already, BOND has been successfully adapted for DMR molecular profiling of experimental cellular samples [@B26] and clinical fine needle aspirate samples [@B25]. Recently, we have developed newer two-step detection schemes based on complementary oligonucleotide approaches [@B29], alternative cycloaddition chemistries [@B49] and cyclodextrin/adamantine supramolecular interactions [@B30].

MINIATURIZED NMR SYSTEMS
========================

A key to sensitive detection in DMR is the miniaturized nuclear magnetic resonance (µNMR) systems (**Fig. [4](#F4){ref-type="fig"}**) [@B21]. The miniaturization of the NMR device brings distinctive advantages. First, it lowers the detection limit by reducing the sample volumes and hence effectively increasing analyte concentrations [@B50]. Second, miniaturized NMR probes (coils) produce much stronger radio-frequency (RF) magnetic fields per unit current, leading to higher signal-to-noise per unit sample volume [@B51]. Third, with smaller RF coils, the requirement for spatial homogeneity of static magnetic fields becomes less stringent, making it possible to use small, portable magnets [@B21].

The first prototype (µNMR-1; **Fig. [4](#F4){ref-type="fig"}a**) was designed to test the feasibility of miniaturization. The system consisted of a microfabricated NMR probe, a small permanent magnet (*B* = 0.5 T), custom-designed NMR electronics, and a microfluidic network [@B21]. The probe had multiple planar microcoils (a 2 × 4 array) to enable parallel detection. In this system, the coils excite biological samples by emitting RF pulses, and subsequently receive resulting NMR signals. The microfluidic networks provide efficient mixing between the samples and MNPs and guide the samples to eight different planar coils. To compensate for the magnetic field inhomogeneity from the small permanent magnet, Carr-Purcell-Meiboom-Gill (CPMG) spin-echo pulse sequences were used for transverse (*T*~2~) relaxation time measurements. To generate versatile pulse sequences while using minimal electronic parts, we devised a new circuit schematic for NMR electronics, that has served as a blueprint for subsequent NMR systems.

The second prototype (µNMR-2) was designed to improve the DMR detection sensitivity by optimizing the NMR probe (**Fig. [4](#F4){ref-type="fig"}B**) [@B28], [@B44]. We selected wire-wound solenoidal coils as the probe format, as they could produce more homogeneous RF magnetic fields and have less electrical resistance. The overall signal-to-noise ratio (SNR) was further enhanced by fully embedding the coils into the fluidic system. In brief, solenoidal coils were prepared by winding insulated wires around a polyethylene tube. The coil-tube assembly was placed on a template for microfluidic systems, and cast-molded by pouring polydimethylsiloxane (PDMS). After PDMS curing, the tube was extracted to open up the entire coil-bore for fluidic access for high filling factor (≈ 1). Combined with lower electrical noise of the coils, the µNMR-2 showed 10-fold higher mass detection sensitivity than µNMR-1, and enabled highly sensitive detection (single mammalian cells, a few bacteria). In parallel with the probe development, we also strategized to miniaturize the entire NMR system. Particularly, we custom-designed a CMOS (complementary-metal-oxide semiconductor) chip (1.4 × 1.4 mm^2^) that integrates all NMR electronics (**Fig. [4](#F4){ref-type="fig"}C**) [@B52], [@B53]. The whole NMR setup could be packaged as a mobile hand-held device, making µNMR-2 the world\'s smallest NMR system.

Most recently, we have developed a third generation µNMR-3 device optimized for routine clinical applications (**Fig. [4](#F4){ref-type="fig"}D**) [@B31]. A major challenge in moving µNMR from a basic science laboratory to a clinical environment has been the system\'s inherent sensitivity to temperature. The latter originates from the temperature-dependent fluctuation of the magnetic field generated by the permanent magnet. These fluctuations lead to drifts in the NMR frequency, resulting in an artifact in the measured *T*~2~ values. In a laboratory setting, the problem can be addressed by controlling the environmental and system temperatures. Such a solution, however, significantly increases the cost and size of the µNMR system, undermining its use for point-of-care applications. In the new µNMR-3, we solved this problem through an electronic approach: we implemented a feedback routine that automatically tracks temperature changes and correspondingly reconfigures the measurement settings. This solution guarantees reliable and robust DMR measurements. For example, when the tracking routine was turned off, *T*~2~ values fluctuated up to 200% of its initial value in a typical laboratory setting. With the tracking on, however, *T*~2~variations considerably decreased (\< 1%; **Fig. [4](#F4){ref-type="fig"}D right**).

The µNMR-3 features other important aspects for practical use. Unlike the previous generations of µNMR, small-form factor NMR electronics (20 × 12 × 5 cm^3^) were assembled using off-the-shelf integrated circuit (IC) chips (e.g., microcontrollers, RF synthesizers), reducing the cost of the system (\<\$200) and enhancing the programmability. Moreover, the µNMR-3 interfaces with mobile devices (e.g., iPhone™, iPAD™) for its operation. This maximizes the portability of µNMR-3 and improves user-friendliness; medical personnel can obtain sample data promptly via customized DMR applications and achieve real-time data logging/sharing over an encrypted wireless network in a remote clinical site. We have recently employed this system in several clinical trials of cancer detection and profiling.

To date, the DMR platform has been successfully applied to sensitively quantify a wide range of biological targets including DNA/mRNA [@B23], [@B54], proteins [@B21], [@B23], [@B55], enzyme activities [@B23], [@B56], [@B57], small molecules/drugs [@B58], [@B59], bacteria [@B21], [@B44], viruses [@B60] and mammalian tumor cells [@B21], [@B25], [@B26], [@B28]. As described previously, the detection mode of DMR depends on the size of its targets. For small targets such as oligonucleotides, proteins and other small molecule metabolites, MRSw sensing has been used. In these examples, MNPs were conjugated with targeting ligands to function as multivalent sensors. In the presence of the analytes, MNP binding and subsequent clustering causes corresponding *T*~2~ changes to indicate the quantity of the targets. Moreover, such assay strategy can also be used to analyze enzymatic activities. For example, specific MNPs have been designed to assess human telomerase (hTERT) activity by hybridizing with the 30-base pair telomeric repeat sequences produced by hTERT activity [@B54]. More recently, myeloperoxidase (MPO) sensors were generated by attaching phenol-containing molecules, such as dopamine or serotonin, to CLIO nanoparticles [@B61]. In the presence of peroxidase activity, tyroxyl radicals were formed to cross-link the nanoparticles. Using this assay configuration, leukocyte-derived MPO has been shown to play a critical role in the pathogenesis of atherosclerotic plaques.

CANCER DETECTION AND PROFILING
==============================

Sensitive detection and rapid profiling of tumor cells in unprocessed biological samples will have significant impact on both biomedical research and clinical practice. DMR molecular profiling of cancer markers (HER2/*neu*, EGFR, and EpCAM) on mammalian cells was initially demonstrated using the first-generation DMR device (µNMR-1) [@B21]. In these early experiments, CLIO nanoparticles were directly conjugated to monoclonal antibodies. Using the second-generation μNMR-2 and the highly magnetic MnFe~2~O~4~nanoparticles, cellular detection sensitivity was remarkably improved [@B28].

Notably, as shown in **Fig. [5](#F5){ref-type="fig"}A**, the detection threshold was reduced to approximately single-cell level, far surpassing the sensitivity of other conventional clinical methods. There was also a good correlation between DMR and other standard methods (e.g., microscopy, flow cytometry and Western blotting; **Figs. [5](#F5){ref-type="fig"}B, C**).

Through these sets of early experiments, the DMR detection platform was shown to not only require far fewer cells than standard alternative approaches, but also produce results much faster (\< 15 minutes). In addition, the DMR platform is ideally suited for rapid multi-target detection, since it can make measurements on few cells in small sample volumes and in a multiplexed manner. The use of BOND strategy has further advanced DMR profiling capabilities. As a universal labeling approach, BOND simplifies the preparation of the targeted MNPs for multiplexing and amplifies nanoparticle binding to cells. As a proof-of-principle analysis, cancer cells were targeted with CLIO nanoparticles via BOND. At a low cell count (\~1000 cells per sample), parallel DMR measurements could be performed rapidly [@B26].

Through the remarkable integration of the DMR and BOND technologies, this chip-based NMR detection platform has been recently applied in clinical trials of cancer cell profiling [@B25]. Single fine-needle aspirates were obtained from a cohort of 50 patients and analyzed directly with the DMR platform for real-time quantification of multiple protein markers. A surprising degree of heterogeneity in protein expression both across the different patient samples and even with the same tumor was observed (**Fig. [6](#F6){ref-type="fig"}A**).

This first clinical study indicated that 1) single fine-needle aspirates contain sufficiently high numbers of cells to enable real-time quantitative analysis of many molecular markers with DMR; 2) using a four-protein signature (HER2/*neu*, EGFR, EpCAM and Muc-1), the DMR platform reports a 96% accuracy for establishing a cancer diagnosis, surpassing conventional clinical analyses by immunohistochemistry (**Fig. [6](#F6){ref-type="fig"}B**). Based on these results, a number of additional clinical trials are currently ongoing. The DMR platform thus represents a novel system for real-time molecular diagnostics close to the patient bedside, and a valuable tool for investigating and establishing tumor heterogeneity and therapeutic drug targeting.

CONCLUSIONS AND PERSPECTIVES
============================

The DMR biosensor platform seamlessly integrates several cutting-edge technologies, namely nanomaterials, bioconjugation chemistry and microfabrication. As a novel technique, it offers a number of synergistic advantages such as high detection sensitivity, rapid target measurement with minimal sample processing, and the ability to profile a wide range of targets in a multiplexed manner from small sample volumes. With recent developments such as the advent of chip-based μNMR devices, optimized magnetic nanomaterials and advanced conjugation techniques, the DMR technology is a highly attractive platform to enable low-cost, and sensitive biomolecular detection in a point-of-care setting.

In addition to having significant practical use for quantitative and molecular analyses in biomedical research, the DMR platform also has far-reaching impact on clinical disease management. The capability to detect and molecularly profile cells with minimal false negatives would accelerate the advance of personalized treatment, by providing valuable information on cellular/molecular signature of individual patients. We further envision a broader application of the DMR platform in global healthcare. As DMR sensing does not require extensive sample purification as do optical methods, and the platform can be packaged as a portable device, the system is thus well-suited for rapid and point-of-care testing, especially in resource-limited primary clinics.
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![**DMR assay configurations.** (A) Magnetic relaxation switching (MRSw) assays detect changes in the organizational states of magnetic nanoparticles (MNPs) in solution. MRSw assays can be designed to cause forward switching, whereby molecular targets cross-link MNPs to induce MNP clustering, thus effecting a corresponding decrease in *T*~2~. Alternatively, the assays can cause reverse switching, where enzymatic cleavage or competitive binding of molecular targets disassembles pre-formed clusters to cause an increase in *T*~2~. (B) Magnetic tagging assays detect the presence of bound MNPs on larger biological entities. Bound MNPs impart a magnetic moment to tagged cells, leading to a decrease in *T*~2~ relaxation time. Unbound MNPs must be removed to ensure detection sensitivity. (C) This gain of magnetic moment (change of 1/*T*~2~) is proportional to the number of MNPs bound; shorter *T*~2~indicates higher expression of the relevant biomarkers. (Reproduced with permission from [@B23] [@B21]. Copyright 2002, 2008 Nature Publishing Group.)](thnov02p0055g01){#F1}

![**Higher r~2~-relaxivity MNPs developed to enhance *in vitro* detection sensitivity.**(A) Transmission electron micrograph (TEM) images of manganese-doped ferrite nanoparticles (MnFe~2~O~4~). These nanoparticles have narrow size distribution and high crystallinity, and were synthesized using a seed-growth method to produce 10, 12, 16, and 22 nm nanoparticles. (B) TEM image of elemental iron (Fe) core/ferrite shell magnetic nanoparticles (CB; cannonballs). These particles have a large Fe core (11 nm) passivated with a thin ferrite shell (2.5 nm) that is produced through controlled oxidation. (C) TEM image of Fe core/ferrite shell magnetic nanoparticles with tunable core size and shell composition. The Fe cores were enlarged into a thermally stable ferromagnetic state to increase the overall magnetization. Protective ferrite shells were then grown onto the cores, without oxidizing the cores, and metal-doped to further enhance magnetization. The resultant particles displayed hysteresis with negligible coercivity. (D) Comparison of size, *r~2~* relaxivity, and saturated magnetization of various doped-ferrite and elemental Fe-based nanoparticles. CLIO, cross-linked iron oxide; MION, monocrystalline iron oxide. (Adapted with permission from [@B28] Copyright 2009 National Academy of Sciences, USA. Reproduced with permission from [@B44]. Copyright 2009 John Wiley and Sons, Inc. Reproduced with permission from [@B45] Copyright 2011 John Wiley and Sons, Inc.)](thnov02p0055g02){#F2}

![**Bioorthogonal nanoparticle detection (BOND) strategy for DMR detection.** Schematics showing the conjugation chemistry and coupling between antibody and nanoparticle. Antibodies against biomarkers were modified with trans-cyclooctene (TCO) and used as scaffolds to couple more tetrazine (Tz) modified nanoparticles onto live cells. The strategy is fast, catalyst-free, specific even in complex biological environment, and amplifies biomarker signals. (Reproduced with permission from [@B26]. Copyright 2010 Nature Publishing Group.)](thnov02p0055g03){#F3}

![**Miniaturized devices developed for DMR biosensing.**(A) The first-generation miniaturized device (µNMR-1) to measure relaxation times of biological samples consists of an array of microcoils for NMR measurements, microfluidic networks for sample handling and mixing, miniaturized NMR electronics and a portable permanent magnet to generate a polarizing magnetic field. (B) The second-generation (µNMR-2) consists of a solenoidal coil embedded in a microfluidic device. As compared to the previous generation, this improved device has a higher filling factor, better signal-to-noise ratio, and reduces sample volume requirement to \~1 μl. (C) 0.1 kg "palm" µNMR-2 system is 20× lighter and 30× smaller than previous generation. To achieve this significant size reduction, a small 0.56 T magnet was used. To compensate for the signal reduction from the smaller magnet, this device incorporates a new RF transceiver fully integrated in the 0.18-μm CMOS. (D) The latest generation of µNMR is equipped with the capability to automatically track and compensate for temperature changes, ensuring robust and reliable *T*~2~ measurements. With the temperature compensation turned on, the measured *T*~2~ values of the same sample showed \<1% variation, whereas *T*~2~ values fluctuated \>200% without such scheme (right). The new system communicates with mobile devices (smartphones, tablet computers) for easy system control and data logging. (Reproduced with permission from [@B24]. Copyright 2008 Nature Publishing Group. Reproduced with permission from [@B28]**.**Copyright 2009 National Academy of Sciences, USA. Reproduced with permission from [@B52]. Copyright 2010 IEEE. Reproduced with permission from [@B31]. Copyright 2011 RSC Publishing.)](thnov02p0055g04){#F4}

![**Tumor cell detection and profiling with DMR.**(A) The detection sensitivity of DMR was approximately two cells (in 1 µl sample volume) using the improved µNMR-2 device (Figure [4](#F4){ref-type="fig"}B) and the highly magnetic MnFe~2~O~4~ nanoparticles (Figure [2](#F2){ref-type="fig"}A) , making this detection platform superior to current clinical methods (cytology and histology). (B and C) Different human breast cancer cells with varying expression of HER2/*neu* and control cells were labeled with MnFe~2~O~4~ nanoparticles. DMR measurements correlated well with standard molecular analyses such as flow cytometry, Western blot and immunofluorescence, but required substantially fewer cells. (Reproduced with permission from [@B28]. Copyright 2009 National Academy of Sciences, USA.)](thnov02p0055g05){#F5}

![**Clinical applications of DMR in tumor diagnostics.** Single fine-needle aspirates were obtained from a cohort of patients, and were tagged via the BOND strategy for DMR detection. (A) Real-time quantification of multiple protein markers with the DMR platform indicates a high degree of heterogeneity in protein expression both across the different patient samples and even with the same tumor. (B) Using a four-protein signature (HER2/*neu*, EGFR, EpCAM and Muc-1), the DMR platform reports a 96% accuracy for establishing a cancer diagnosis, surpassing conventional clinical analyses by immunohistochemistry. (Reproduced with permission from [@B25]. Copyright 2011 American Association for the Advancement of Science AAAS.)](thnov02p0055g06){#F6}
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